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Abstract
Background: Arginine is an amino acid determinant in the metabolic, immune and reparative responses to severe
trauma. The present study aims to determine argininemia and plasma arginine bioavailability (PAB) in critical trauma
patients and to analyze its correlation with prognosis.
Methods: A prospective study of 23 critical trauma patients was undertaken. Aminoacidemias were determined, by
ion exchange chromatography, at admission and in the first and third days and compared with those of 11 healthy
individuals. PAB was calculated. Severity indexes and outcome parameters were recorded.
Results: Values of argininemia, citrullinemia and ornithinemia at the admission were significantly lower than those
of the controls (arginine: 41.2 ± 20.6 versus 56.1 ± 11.9 μmol/L, P = 0.034). Hipoargininemia (<60 μmol/L) prevalence
was 82.6 %. Mean PAB was 62.4 ± 25.6 %. Argininemia < 26 μmol/L constituted a significant predictive factor of in-hospital
mortality [n = 4 (17.4 %); 75 versus 15.8 %, P = 0.04; odds ratio = 4.7; accuracy = 87 %] and lower actuarial survival (63.5 ±
43.9 versus 256.1 ± 33.3 days, P = 0.031). PAB <42 % [n= 6 (26.1 %)] was associated with higher lactacidemia levels (P = 0.
033), higher in-hospital mortality (66.7 versus 11.8 %, P = 0.021; odds ratio = 5.7, accuracy = 82.6 %) and lower actuarial
survival (87.2 ± 37.5 versus 261.4 ± 34.7 days, n.s.). Probability of in-hospital mortality was inversely and significantly related
with PAB [61.8 ± 8.8 % (95 % CI 50.8–72.7) when PAB <41 % and 2.8 ± 1.9 % (95 % CI 1.9–8.3) when PAB > 81 %, P = 0.
0001]. Charlson’s index ≥1, APACHE II ≥19.5, SOFA ≥7.5, and glutaminemia < 320 μmol/L were also predictive factors of
actuarial survival.
Conclusions: Those results confirm the high prevalence of arginine depletion in severe trauma patients and the
relevance of argininemia and PAB as predictive factors of mortality in this context.
Keywords: Arginine, Plasma arginine bioavailability, Trauma, Mortality, Critically ill patients
Abbreviations: 95 % CI, 95 % Confidence interval; APACHE II, Acute Physiology and Chronic Health Evaluation
II; Arg-to-Orn, Argininemia-to-ornithinemia; auROC, Area under the “receiver operating characteristic curve”;
ICU, Intensive care unit; n.s., Statistically not significant; NOS, Nitric oxide synthase; r, Pearson’s correlation
coefficient; SAPS II, Simplified Acute Physiology Score II; SD, Standard deviation; SOFA, Sequential Organ failure
assessment; vs, Versus
* Correspondence: beatrizpcosta@huc.min-saude.pt; beatrizpcosta@iol.pt
1“A” Surgical Department, Hospitais da Universidade de Coimbra, Centro
Hospitalar e Universitário de Coimbra, Praceta Prof. Mota Pinto, 3000-075
Coimbra, Portugal
2Faculty of Medicine, University of Coimbra, Coimbra, Portugal
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Costa et al. Nutrition & Metabolism  (2016) 13:60 
DOI 10.1186/s12986-016-0118-6
Background
Arginine is a conditionally essential amino acid involved in
protein synthesis; ureagenesis and ammonia detoxification;
nitric oxide metabolism; production of proline (used for
collagen synthesis and tissue repair), polyamines (primary
regulators of cellular growth and proliferation), creatine
and agmatin; and hormonal secretion (including growth
hormone, insulin and prolactin) [1–4]. Arginine partici-
pates in the modulation of the immune function (including
T-lymphocytes proliferation and activation), inflammatory
response, tissue perfusion, wound healing and airway tonus
control [1–3].
Circulating arginine derives from protein turnover,
de novo endogenous synthesis (in the kidney from gut-
produced citrulline via the urea cycle) and dietary protein
sources [4]. Arginine is metabolized predominantly by two
competing pathways, namely nitric oxide synthases (NOSs)
and arginases (I and II) as part of the urea cycle. Arginases
transform arginine into ornithine (precursor of proline and
polyamines) and urea, whereas NOSs convert arginine into
nitric oxide and citrulline. Arginase I is found in the cytosol
of hepatocytes and leukocytes, while arginase II is a mito-
chondrial enzyme present in the macrophages and numer-
ous other cells [4, 5]. Three isoforms of NOS are relevant:
NOS 1 (neuronal) and NOS 3 (endothelial) that are consti-
tutive enzymes; and NOS 2 (inducible) that is markedly
induced during inflammation. Both arginase I and inducible
NOS (iNOS) are inducible enzymes in myeloid cells, with
arginase I being induced by T-helper 2 (Th2) cytokines and
iNOS by T-helper 1 (Th1) cytokines [4–6]. Preponderant
type of reaction is influenced by the nature of injury [7],
namely Th2 response in trauma and major surgery and
Th1 response in sepsis.
Systemic arginine availability has been estimated by
calculation of the ratios of arginine to its enzymatic
products (citrulline and ornithine) and arginine to its en-
dogenous metabolic inhibitors (asymmetric and symmet-
ric dimethylarginines) [8]. Plasma arginine bioavailability
(PAB) is defined by the argininemia-to-(citrullinemia
plus ornithinemia) quotient [9, 10]. PAB constitutes an
indirect measure of the arginine endogenous synthesis
and of the arginase activity; and, also, a reflex of the
oxide nitric production [9], which is recognized as an
important signaling agent with vasodilatation, cytotoxicity
and neurotransmission effects [2, 11–13]. PAB is con-
sidered, in several contexts, a bioindicator of arginine
metabolism deregulation more accurate than isolated
argininemia [9, 10].
Arginine is determinant in the metabolic, immune and
reparative responses to severe trauma [14], which consti-
tutes the leading cause of mortality in the first four de-
cades of life [15, 16]. Arginine depletion is frequent in
severe trauma patients and has a potential relevant im-
pact in the prognosis [14, 15].
Present study aims to determine the profile of plasma
concentrations of arginine, citrulline and ornithine in
critical trauma patients; to calculate plasma arginine bio-
availability; and to analyze their correlation with the se-
verity indexes and the clinical outcome.
Methods
A single-center observational prospective study of adult
critical trauma patients non-electively admitted in the
Intensive Care Unit (ICU) of Hospitais da Universidade
de Coimbra, Centro Hospitalar e Universitário de Coimbra,
Coimbra, Portugal was undertaken between October 2013
and April 2014. Included patients fulfilled the Intensive
Care Society definition of critically illness [17] and were
expected to require an ICU length of stay of at least three
days. Exclusion criteria included pregnancy, lactation,
acquired immunodeficiency syndrome, renal insuffi-
ciency (creatininemia ≥ 2 mg/dL), acute liver failure
(defined according the criteria previously described by
O’Grady JG et al. [18] and Moreau R et al. [19]) and
amino acid metabolism diseases.
Study was approved by the institution’s ethics committee
(Centro Hospitalar e Universitário de Coimbra, Coimbra,
Portugal; Official Letter n° CHUC00115) and was per-
formed following the principles established by the Helsinki’s
declaration [20].
Patients’ demographic characteristics were acquired,
including age and gender. Type of admission was char-
acterized as primary or non-primary (after previous ini-
tial care on peripheral hospitals). Severity indexes were
registered at the moment of admission, including Acute
Physiology and Chronic Health Evaluation II (APACHE
II) score [21], Simplified Acute Physiology Score II
(SAPS II) [22], Sequential Organ Failure Assessment
(SOFA) score [23], Abbreviated Injury Scale [24], Injury
Severity Score [25], Revised Trauma Score [26] and
Shock Index [27]. In addition, comorbidities were de-
scribed with the Charlson’s index [28]. Invasive venti-
lation, erythrocytes transfusions, amines perfusion,
renal replacement therapy, surgical procedures and
nutritional support were recorded, as well as, glutam-
ine exogenous supplementation. Standard formulas
were used in enteral nutrition support; intravenous
administration of glutamine was prescribed in patients
submitted to parenteral nutrition, at the dose of 0.2–
0.4 mg/kg/day.
Evaluation was performed at the moment of admission
in the ICU, at the first and the third days, with determin-
ation of amino acid plasma levels (arginine, citrulline,
ornithine, glutamine, alanine, proline, glutamic acid, leu-
cine and isoleucine) and regular laboratory tests (including
blood gases analysis; lactacidemia; serum biochemistry
with hepatobiliary enzymes, ionograme, creatinine, albu-
min, lactate dehydrogenase, creatinephosphokinase and
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C-reactive protein; hemograme; caolin-cefalin and
prothombin times).
Plasma concentrations of amino acids were studied by
ion exchange chromatography in a high pressure system
(Biochrom 30 analyzer). Plasma was extracted from
blood sampled in ethilenediaminotetraacetic acid, by
centrifugation at 4000 g, during 10 min, and reserved at
4 °C; samples were prepared with 12 % ditiotreitol, five
to 10 min, deproteinized with sulfosalicilic acid, 60 min at
room temperature and, after separation of the sediment
by centrifugation, were filtered and preserved at −20 °C
for subsequent analysis.
Plasma arginine bioavailability (PAB) was calculated
in accordance to the formula: argininemia:(citrullinemia +
ornithinemia) [9, 12] and expressed in percentage. Arginase
activity was estimated by the argininemia-to-ornithinemia
ratio [8].
Amino acid plasma concentrations of critical trauma
patients were compared with those of a historical con-
trol group of eleven fasting healthy individuals [29].
Primary end-points included in-hospital mortality rate
and actuarial survival. Secondary end-points were health
care-associated infections rate [30], duration of invasive
ventilation support, hospital and ICU lengths of stay and
performance status at the moment of the last observa-
tion (characterized by the Karnofsky index [31]). Health
care-associated infections were defined according the
surveillance definition in the acute care setting of the
National Healthcare Safety Network (NSHN), Centers
for Disease Control and Prevention (CDC), Atlanta, GA,
USA [30].
Statistical analysis was performed with SPSS Software
version 18.0 for Windows (SPSS Inc., Chicago, IL, USA).
Qui-square, Student’s t, paired Student’s t, Kaplan Meier
and log rank tests, multivariable logistic regression, Cox’s
regression, Pearson’s correlations and Receiver Operating
Characteristic (ROC) curves were used. Level of signifi-
cance was considered P < 0.05. Data were presented as n
(%) or mean ± standard deviation (SD).
Results
Twenty-three critical trauma patients were studied and
presented the characteristics described in Table 1. Deter-
mination of plasma amino acid profile was accomplished
in all patients at the ICU admission; in 18 both at the
admission and the first day; only 12 patients completed
the three moments of evaluation.
At the moment of admission in ICU, critical trauma
patients demonstrated lower mean values of argininemia,
citrullinemia and ornithinemia than fasting historical
control individuals (argininemia: 41.2 ± 20.6 versus 56.1 ±
11.9 μmol/L, P = 0.034; citrulline: 19.5 ± 11.1 versus 32.2 ±
6.6 μmol/L, P = 0.001; ornithine: 49.6 ± 20.6 versus 94.6 ±
17.9 μmol/L, P = 0.0001); they also exhibited lower mean
levels of glutaminemia and alaninemia and higher mean
glutamic acid plasma concentration (Fig. 1). Hipoargi-
ninemia (argininemia inferior to 60 μmol/L) preva-
lence at the ICU admission was high (82.6 %). Initial
mean plasma arginine bioavailability (PAB) in severe
trauma patients was 62.4 ± 25.6 %, not significantly
different from that of control individuals (46 ± 14.7 %)
(Fig. 2). Argininemia-to-ornithinemia ratio in trauma pa-
tients at the ICU admission was higher than in control
subjects (89.2 ± 36.2 versus 61.9 ± 20.5 %, P = 0.009).
During the first three days of ICU stay, a decrease of glu-
taminemia and an increase of ornithinemia and glutamic
Table 1 Critical trauma patient’s characteristics (n = 23)
n (%) or mean ± SD
Male gender 18 (78.3)
Age (years-old) 48.8 ± 17.8 (21–82)
Charlson’s comorbidity index 0.78 ± 1.98 (0–8)
Primary admission 18 (78.3)
APACHE II 19.4 ± 5.5 (10–32)
SAPS II 41.3 ± 12.2 (20–78)
SOFA 6.9 ± 3.2 (2–10)
Shock index 0.82 ± 0.25 (0.31–1.4)
Abbreviated Injury Scale 15.4 ± 4.9 (10–25)
Injury Severity Score 47.9 ± 18.5 (27–75)
Revised Trauma Score 5.9 ± 1.3 (3.6–7.6)
Invasive ventilation 23 (100)
Renal replacement therapy 0 (0)
Amines perfusion 16 (69.6)
Erythrocytes transfusion 14 (60.9)
Nutritional support
Enteral/Parenteral 23 (100)/1 (4.3)
Glutamine supplementationa 1 (4.3)
Surgical proceduresb 14 (65.2)
Mortality rate




Ventilation support (days) 12.7 ± 7.8 (2–27)
Length of stay (days)
ICU/Hospital (days) 13.9 ± 9.1 (3–52)/29.4 ± 21.9 (5–95)
Follow-up (months) 7.4 ± 3.1 (2.3–12.2)
Actuarial survival (days) 229.2 ± 32.9 (95 % CI 164.7–293.8)
Karnofsky’s index 69 ± 17.3 (40–90)
Data presented as number (%) or mean ± standard deviation
APACHE II acute physiology and chronic health evaluation II, ICU intensive care
unit, SAPS II simplified acute physiology score II, SD standard deviation, SOFA
sequential organ failure assessment
aGlutamine was administered after the third day in the intensive care unit
bOperations before intensive care unit admission (n = 4); operations after the
third day in intensive care unit (n = 5)
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Fig. 1 Mean aminoacidemia levels in critical trauma patients (n = 23) at the moment of the admission in the intensive care unit (ICU) and at the
first and the third days; and in control healthy individuals (n = 11). Comparisons were performed with Student’s-t test (with control group) and
paired Student’s-t test (between the ICU moments of evaluation). * Plasma levels × 10−1. Controls corresponded to a historical cohort of healthy
individuals [29]
Fig. 2 Mean plasma arginine bioavailability (PAB), argininemia, citrullinemia and ornithinemia in critical trauma patients (n = 23) at the moment of
the admission in the intensive care unit (ICU) and at the first and the third days; and in control healthy individuals (n = 11). Controls corresponded to a
historical cohort of healthy individuals [29]
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acid plasma levels were observed; no significant differences
were verified in the remaining amino acid concentrations
(including argininemia and citrullinemia), PAB or
argininemia-to-ornithinemia ratio between the three
moments of evaluation.
At the moment of admission, argininemia and PAB did
not correlate significantly with patients’ age, Charlson’s
index and severity scores, including APACHE II, SAPS II,
SOFA, Abbreviated Injury Scale, Injury Severity Score,
Revised Trauma Score and Shock Index; furthermore, no
significant differences were observed in those parameters
according gender, type of admission or submission to
previous surgical procedures. Argininemia at the moment
of admission correlated significantly with glutaminemia
[Pearson’s correlation coefficient (r) = 69.5 %, P = 0.0001],
ornithinemia (r = 55.6 %, P = 0.006), C-reactive protein
(r = 71.1 %; P = 0.006) and albuminemia (r = 70.1 %; P =
0.008).
Argininemia values lower than 26 μmol/L at the admis-
sion were significantly associated with higher in-hospital
mortality rate, shorter duration of invasive ventilation and
ICU length of stay and lower mean actuarial survival
(Table 2). PAB levels inferior to 42 % at the admission
were significantly associated with higher in-hospital mor-
tality rate. Initial argininemia and PAB values were not
significantly related with the development of nosocomial
infections.
In univariate analysis, Charlson’s index superior or
equal to one, argininemia lower than 26 μmol/L and
PAB inferior to 42 % were risk factors of in-hospital
mortality; only Charlson’s index was significant in multi-
variate analysis (P = 0.045) (Table 3). Cases of in-hospital
mortality demonstrated lower mean plasma concentra-
tions of arginine, glutamine and alanine and higher
mean levels of proline and glutamic acid, however with-
out reaching statistically significant differences.
In univariate analysis, Charlson’s index superior or
equal to one, APACHE II superior or equal to “19.5”,
SOFA score superior or equal to “7.5”, argininemia lower
than 26 μmol/L and glutaminemia inferior to 320 μmol/L
were predictive factors of lower actuarial survival (Table 3;
Fig. 3); none of those factors was significant in multivari-
ate analysis.
Argininemia values inferior to 26 μmol/L, observed in
17.4 % of severe trauma patients, constituted significant
predictive factors of in-hospital mortality [75 versus
15.8 %, P = 0.04; odds ratio = 4.7 (95 % CI 1.5–15.9); ac-
curacy = 87 %; sensitivity = 57.1 %; specificity = 94.1 %;
negative predictive value = 84.1 %; positive predictive
value = 100 %] and of lower actuarial survival (63.5 ±
43.9 versus 256.1 ± 33.3 days, P = 0.031).
PAB revealed a significant and high predictive capacity
of in-hospital mortality [42.3 ± 14.7 % in cases of mortal-
ity versus 69.4 ± 25.1 % in remaining cases, P = 0.022;
auROC = 79.4 ± 9.7 % (95 % CI 60.4–98.4), P = 0.032].
Probability of in-hospital mortality, calculated by the lo-
gistic regression model, was inversely and significantly
related with PAB: 61.8 ± 8.8 % (95 % CI 50.8–72.7) when
PAB inferior to 41 %, 21.3 ± 11.5 % (95 % CI 14.4–28.3)
between 41 and 81 % and 2.8 ± 1.9 % (95 % CI 1.9–8.3)
when PAB superior to 81 % (P = 0.0001) (Fig. 4).
PAB lower than 42 % at the admission, observed in
26.1 % of critical trauma patients, was associated with
higher lactacidemia levels (3.68 ± 1.76 versus 1.95 ±
1.5 mmol/L, P = 0.033); higher in-hospital mortality
[66.7 versus 11.8 %, P = 0.021; odds ratio = 5.7 (95 % CI
1.4–23.3), accuracy = 82.6 %; sensitivity = 66.7 %; specifi-
city = 88.2 %; negative predictive value = 88.2 %; positive
predictive value = 66.7 %]; and lower actuarial survival
(87.2 ± 37.5 versus 261.4 ± 34.7 days, n.s.).
Discussion
In the present study, mean arginine plasma levels of crit-
ical trauma patients at the admission on the ICU were
lower than those of the historical healthy control individ-
uals [29] and similar to those described in the literature
for critically ill subjects [1, 32, 33].
Table 2 Clinical outcome of critical trauma patients (n = 23) according to argininemia and plasma arginine bioavailability at the ICU
admission
Argininemia
<26 μmol/L vs ≥26 μmol/L
Pa Plasma arginine bioavailability
<42 % vs ≥42 %
Pa
In-hospital mortality (%) 75 vs 15.8 0.04 66.7 vs 11.8 0.021
Health care-associated infections rate (%) 75 vs 89.5 n.s. 83.3 vs 88.2 n.s.
Invasive ventilation period (days) 6.3 ± 3.5 vs 14.1 ± 7.8 0.01 8.5 ± 6.7 vs 14.2 ± 7.7 n.s.
ICU length of stay (days) 7 ± 3.6 vs 15.4 ± 9.3 0.01 9.5 ± 6.7 vs 15.5 ± 9.5 n.s.
Hospital length of stay (days) 15.3 ± 9.3 vs 32.4 ± 22.8 n.s. 21.8 ± 17.8 vs 32.1 ± 23.1 n.s.
Mean actuarial survival (days) 63.5 ± 43.9 vs 256.1 ± 33.3 0.031 87.2 ± 37.5 vs 261.4 ± 34.7 n.s.
Performance status (Karnofsky’s index) 50 ± 0 vs 71.1 ± 16.9 n.s. 65 ± 21.2 vs 70 ± 17.7 n.s.
Data presented as number (%) or mean ± standard deviation
ICU intensive care unit, vs versus
aQui-square, Student’s-t, Kaplan Meier and log rank tests
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Trauma is characterized by an arginine deficiency state
associated with increased catabolism of this amino acid
[5, 15], driven mainly by the marked upregulation of
arginase in several tissues [4], proportional to the sever-
ity of the injury [34]; and further aggravated by the re-
duction of de novo synthesis and of dietary intake [4].
Trauma increases the expression of T-helper 2 lympho-
cytes, consequent to the activation of the hypothalamic-
pituitary-adrenal axis and sympathoadrenal system, which
cause impaired cell mediated immunity [5]. Furthermore,
T-helper 2 cytokines increase the expression of arginase I
in immature myeloid-derived suppressor cells causing
arginine depletion, which further impairs T-lymphocyte
function (increasing the risk of infections) and nitric oxide
production [5].
In this series of trauma patients, argininemia at the
ICU admission did not correlate significantly with severity
and prognosis indexes. PAB lower than 42 % was associ-
ated with higher lactacidemia levels, considered markers
of circulatory failure [32]. Arginase activity, estimated by
the argininemia-to-ornithinemia ratio [8], was higher in
severely traumatized patients at the ICU admission than
in historical control individuals, as expected [5, 34].
Argininemia and PAB did not suffer significant variations
during the first three days of ICU stay.
Unexpectedly, argininemia and PAB were not signifi-
cantly related with the development of infectious
complications. In fact, T-lymphocytes depended on
arginine for proliferation and activation, zeta-chain
peptide and T-cell receptor complex expression and
development of memory [7]. The relatively high inci-
dence of health care-associated infections (87 %) in
this study may have prevented the observation of the
effects of hipoargininemia.
In present study, PAB lower than 42 % revealed to be
highly predictive of in-hospital mortality and argininemia
values lower than 26 μmol/L were significantly associated
with lower actuarial survival in severe trauma patients.
Previously, Gey A et al. [35] demonstrated a marked
increase of granulocytic myeloid-derived suppressor cells
in critically ill patients admitted in a medical ICU, which
was inversely correlated with plasma arginine concentra-
tions and overall survival. Other authors demonstrated,
also, that high plasma levels asymmetric dimethylarginine
(an endogenous inhibitor of NOS) and low arginine-to-
asymmetric-dimethylarginine ratio constitute independent
risk factors for organ failure and ICU mortality [13, 32].
Nevertheless, arginine supplementation in the critically ill
patients remains controversial [4, 36, 37]. Analysis of its re-
sults has been hampered by the heterogeneity of the stud-
ied populations, differences in the arginine administration
schedule (type of immune-modulating formula, timing and
dosage), simultaneous provision of other immunonutrients
and poor methodological quality of some studies [36].
Table 3 Univariate analysis of in-hospital mortality and actuarial survival in critical trauma patients (n = 23)
(%) In-hospital mortality (%) Pa Mean survival (days) Pb
Male gender (78.3) 27.8 vs 20 n.s. 218.2 ± 36.4 vs 243.6 ± 66.5 n.s.
Age ≥ 60 years-old (30.4) 42.9 vs 18.8 n.s. 103.7 ± 30.7 vs 265.5 ± 37.5 n.s.
Charlson’s Index ≥ 1 (17.4) 75 vs 15.8 0.04 57 ± 34.3 vs 266.2 ± 33.8 0.005
APACHE II ≥ 19.5 (50) 45.5 vs 9.1 n.s. 152 ± 43.5 vs 310.7 ± 35.4 0.031
SAPS II ≥ 39.5 (54.6) 41.7 vs 10 n.s. 167.3 ± 42.4 vs 305 ± 38.6 n.s.
SOFA ≥ 7.5 (53.9) 42.9 vs 0 n.s. 0.039
Injury Severity Score < 65 (73.9) 35.3 vs 0 n.s. 192.2 ± 37.6 vs 315.7 ± 45 n.s.
Revised Trauma Score ≥ 4.8 (78.3) 33.3 vs 0 n.s. n.s.
Shock index ≥ 0.75 (54.6) 41.7 vs 10 n.s. 196.5 ± 48.9 vs 273.3 ± 39.3 n.s.
Primary admission (yes vs no) (21.7) 40 vs 22.2 n.s. 173.6 ± 70.7 vs 237.2 ± 35.1 n.s.
Lactacidemia ≥ 1.25 mmol/L (63.6) 35.7 vs 12.5 n.s. 207.6 ± 42.9 vs 275.3 ± 48 n.s.
Arginine bioavailability < 42 % (26.1) 66.7 vs 11.8 0.021 87.2 ± 37.5 vs 261.4 ± 34.7 n.s.
Argininemia < 26 μmol/L (17.4) 75 vs 15.8 0.04 63.5 ± 43.9 vs 256.1 ± 33.3 0.031
Glutaminemia < 320 μmol/L (21.7) 60 vs 16.7 n.s. 70.6 ± 34.1 vs 264.8 ± 34.2 0.02
Citrullinemia ≥ 22 μmol/L (26.1) 50 vs 17.6 n.s. 151.5 ± 52.8 vs 241.2 ± 36.6 n.s.
Ornithinemia ≥ 72 μmol/L (17.4) 50 vs 21.1 n.s. 182.5 ± 76.7 vs 235.7 ± 35.6 n.s.
Arg-to-Orn ratio < 77 % (47.8) 45.5 vs 8.3 n.s. 172.1 ± 45.6 vs 268.7 ± 40.2 n.s.
Data presented as number (%) or mean ± standard deviation
APACHE II acute physiology and chronic health evaluation II, Arg-to-Orn Argininemia-to-ornithinemia, SAPS II simplified acute physiology score II, SOFA sequential
organ failure assessment, vs versus
aQui-square test
bKaplan-Meier actuarial survival and log rank test
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Fig. 3 Actuarial survival curves in critical trauma patients (n = 23) admitted in the intensive care unit according Charlson’s index, APACHE II score, SOFA
score, argininemia, glutaminemia and plasma arginine bioavailability at the moment of admission (Kaplan-Meyer curves and log rank test). APACHE II
Acute Physiology and Chronic Health Evaluation II, SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure Assessment
Fig. 4 Probability of in-hospital mortality in critical trauma patients (n = 23) according the plasma arginine bioavailability (PAB) at the moment of
the admission in the intensive care unit, calculated by the logistic regression model. Mortality was inversely and significantly related with PAB:
61.8 ± 8.8 % (95 % CI 50.8–72.7) when PAB inferior to 41 %, 21.3 ± 11.5 % (95 % CI 14.4–28.3) between 41 and 81 % and 2.8 ± 1.9 % (95 % CI
1.9–8.3) when PAB superior to 81 % (P = 0.0001)
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High arginine-containing immune-modulating diets
were recommended to be considered in severe trauma
patients by the European Society of Clinical Nutrition
and Metabolism [38] and by the Society of Critical Care
Medicine/American Society of Enteral and Parenteral
Nutrition [39]; on the contrary, routine arginine
supplementation was discouraged in severe sepsis by both
guidelines [38, 39]. Different responses to exogenous argin-
ine in both arginine deficient states may be related with the
predominant induction of arginase I after trauma while
iNOS expression is increased in patients with sepsis [4, 5].
Putative deleterious effects of arginine administration
in severe sepsis was attributed to the potential overpro-
duction of nitric oxide by iNOS causing detrimental
systemic vasodilatation with worsening of hemodynamic
instability and peroxinitrite formation with cellular dam-
age [40]. Nevertheless, adequate levels of nitric oxide
seem to be necessary in sepsis to ensure organ perfusion
[40–43]. According Gough MS et al. [8], in patients with
severe sepsis, the ratio of arginine-to-dimethylarginine is
reduced, proportionally to the severity of the illness, and
predicts the outcome. Hirose T et al. [44] demonstrated
that minimum values of argininemia were significantly
lower in non-surviving than in surviving septic ICU
patients. Recently, potential benefits of arginine mono-
supplementation during sepsis have been reanalyzed in
experimental and clinical studies [24, 42].
Present series was characterized by the small number
of studied patients and high severity scores. Nevertheless,
hipoargininemia and low PAB represented pejorative prog-
nostic factors. So, further research seems to be necessary to
precisely identify patients that may benefit from arginine
replacement, through biomarkers of the severity and type
of arginine deficiency (such as argininemia, arginine bio-
availability, arginase activity and nitric oxide metabolites).
Additional dietary strategies to restore arginine plasma con-
centration can be studied, including the enteral supplemen-
tation of citrulline that, compared with arginine, may be
associated with higher intestinal absorption, better gastro-
intestinal tolerance, absence of hepatic uptake (without
inducing urea synthesis) and minimization of the risk of
excessive production of nitric oxide [45].
Conclusion
In conclusion, present results confirm the high prevalence
of arginine depletion in severe trauma patients and the rele-
vance of argininemia (<26 μmol/L) and plasma arginine
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